Peter Greenleaf
CIK 1363683 · Chief Executive Officer · last filed 2026-07-07
Peter Greenleaf is a Chief Executive Officer who has filed 60 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider sold $20.8K of PTHS on Jul 7, 2026. Across all open-market trades the lifetime net is −$7.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $29.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$29.71M
10
60
-$7.58M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTHS | Director | 23,969 | $27.77 | $665.6K | -$37.5K | 4 | 2026-07-07 |
| AUPH | Chief Executive Officer | 1,941,269 | $14.96 | $29.04M | -$4.22M | 10 | 2026-03-03 |
| ANTARES PHARMA, INC. (ATRS) Delisted | Director | 79,645 | $5.59 | $445.2K | $0 | 4 | 2021-06-14 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Chief Executive Officer | 112,500 | $2.93 | $329.6K | $0 | 3 | 2019-10-03 |
| EYEG | Director | — | $34.73 | — | $0 | 2 | 2019-02-05 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Chief Executive Officer | 412,500 | — | — | $49.8K | 4 | 2018-05-21 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Chief Executive Officer | 0 | — | — | -$3.37M | 16 | 2018-02-13 |
| MSTX | Director | — | $8.58 | — | $0 | 3 | 2017-01-23 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | — | — | — | $0 | 3 | 2016-09-06 |
| MEDI | SVP, Sales and Marketing | — | $33.42 | — | $0 | 2 | 2007-06-19 |
Recent Filings
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-07 | PTHS | Sell (S) | −797 | -$20.8K | EDGAR |
| 2026-05-11 | AUPH | Notice (144) | −3,136,201 | -$49.68M | EDGAR |
| 2026-04-06 | PTHS | Sell (S) | −797 | -$16.7K | EDGAR |
| 2026-04-01 | PTHS | Grant (A) | +25,478 | $0 | EDGAR |
| 2026-03-03 | AUPH | Mixed | +95,513 | -$1.43M | EDGAR |
| 2026-02-23 | AUPH | Tax (F) | −100,171 | -$1.44M | EDGAR |
| 2026-01-05 | AUPH | Mixed | +52,215 | -$1.81M | EDGAR |
| 2025-07-07 | PTHS | Grant (A) | — | $0 | EDGAR |
| 2025-03-04 | AUPH | Mixed | +263,893 | -$2.87M | EDGAR |
| 2024-03-07 | AUPH | Sell (S) | −126,981 | -$711.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.